CRA International vs Exponent
CRAI and EXPO side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CRAI and EXPO compare
Exponent is the larger company, worth 3.2 times as much as CRA International ($4.2B against $1.3B).
On earnings, CRA International is cheaper: it trades at 27.9× trailing earnings, against 39.3× for Exponent.
Exponent grew revenue faster over the last twelve months (12.8% versus 11.5% for CRA International).
Exponent keeps more of each dollar of sales as profit, with a net margin of 17.7% compared with 6.2% at CRA International.
Both pay dividends: CRA International yields 1.1% and Exponent 1.4%.
Exponent scores higher on the StockData Score (20 against 12 for CRA International), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CRAI | EXPO |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | $4.2B |
| Share price | $209.66 | $87.69 |
| Change, 1 year | 15.9% | 25.4% |
| Change, 5 years | 116% | −24.9% |
| Beta (5Y) | −0.11 | 0.24 |
| Employees | 597 | 1,313 |
| StockData Score | ||
| Total score | 12 | 20 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 2 | 3 (better) |
| Performance score | 5 | 5 |
| Health score | 2 | 6 (better) |
| Dividend score | 3 | 4 (better) |
| Valuation | ||
| P/E | 27.9× (better) | 39.3× |
| P/S | 1.7× (better) | 6.6× |
| P/B | 7.2× (better) | 14.4× |
| EV/EBITDA | 13.9× (better) | 29.8× |
| P/FCF | – | 38.4× |
| PEG | 2.48 (better) | 21.41 |
| FCF yield | −2.1% | 2.6% (better) |
| Fair value | $160.82 | $66.46 |
| Margin of safety | −30.4% (better) | −31.9% |
| Growth | ||
| Revenue growth (TTM) | 11.5% | 12.8% (better) |
| Revenue growth, 5Y average | 8.1% (better) | 7.8% |
| Net income growth (TTM) | −12.8% | 8.7% (better) |
| EPS growth (TTM) | −9.1% | 11.5% (better) |
| EPS growth, 5Y average | 21.5% (better) | 6.0% |
| Profitability | ||
| Gross margin | 29.0% | – |
| Operating margin | 10.0% | 20.2% (better) |
| Net margin | 6.2% | 17.7% (better) |
| FCF margin | −3.5% | 17.2% (better) |
| Return on equity | 26.0% | 31.2% (better) |
| Return on invested capital | 32.0% | 43.8% (better) |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | 11.2× | – |
| Current ratio | 0.82 | 1.98 (better) |
| Altman Z-score | 3.41 | 10.26 (better) |
| Piotroski F-score | 7 (better) | 5 |
| Dividends and buybacks | ||
| Dividend yield | 1.1% | 1.4% (better) |
| Payout ratio | 29.2% | 54.8% |
| Years of dividend growth | 9 | 13 (better) |
| Dividend growth, 5Y average | 16.5% (better) | 9.6% |
| Buyback yield | 4.1% | 5.1% (better) |
| Shareholder yield | 5.1% | 6.5% (better) |
| Ownership | ||
| Held by institutions | 94.8% | 97.8% |
| Held by insiders | 3.7% | 1.3% |
| Insider net buying, 12 months | −$6.2M | −$2.7M (better) |
| Short interest, % of float | 5.0% | 5.2% |
Go deeper
- CRAI stock overview
- CRAI income statement
- CRAI valuation and score
- EXPO stock overview
- EXPO income statement
- EXPO valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.